$8.72
+0.36 (+4.31%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ATRA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 2 expanded access · 3 with posted results
Held by 4 tracked-famous managers (Point72 Asset Management, L.P., JANE STREET GROUP, LLC, MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC) · FINRA short interest 9.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus ErythematosusNCT06429800Number of Participants With treatment-emergent adverse events, including adverse events of special interestNon-randomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Financial | Drug: ATA3219 | Lupus Nephritis, Systemic Lupus Erythematosus | 0 | 2025-04-16actual | 2025-04-24 |
| A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin LymphomaNCT06256484Incidence and Severity of Treatment-emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Financial reasons | Drug: ATA3219 | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | 1 | 2025-03-03actual | 2026-03-11 |
| Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple SclerosisNCT03283826Part 1: Incidence of adverse eventsRandomized · Double-masked · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Study was terminated as primary endpoint was not achieved | Biological: ATA188 · Drug: Placebo | Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | 134 | 2023-11-09actual | 2024-02-23 |
| Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)NCT03769467results2024-11-14Cohort 1B: Number of Participants With Dose-Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Phase 1B part was completed with review of DLTs and cumulative safety data by Safety Data Review Committee and identification of a safe RP2D. Post-internal review, sponsor decided to terminate the study, and hence, Phase 2 part was not conducted. | Biological: Tabelecleucel, Pembrolizumab | Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections, Epstein-Barr Viraemia, Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | 12 | 2021-08-19actual | 2024-11-14 |
| Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or MalignanciesNCT00002663results2023-02-13Objective Response Rate (ORR)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) | EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma | 58 | Jul 2019actual | 2023-02-13 |
| Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated MalignanciesNCT01498484results2022-10-21Objective Response Rate (ORR)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: EBV-specific T cells (EBV-CTLs) | EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma | 87 | Jul 2019actual | 2022-10-21 |
| Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or MalignanciesNCT02822495expanded access | — | No longer available | Biological: tabelecleucel | Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma, EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Epstein-Barr Viremia, Lymphoma, AIDS-related, Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Primary Immunodeficiency (PID), Leiomyosarcoma (LMS), Nasopharyngeal Carcinoma (NPC), Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Acquired Immunodeficiency (AID), Solid Organ Transplant Complications, Stem Cell Transplant Complications | — | — | 2023-06-15 |
| Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or DiseaseNCT03010332expanded access | — | No longer available | Biological: Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs) | CMV Viremia, CMV Disease | — | — | 2019-04-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19